| Literature DB >> 25849086 |
Ching-Yu Lin1, Feng-Peng Huang1, Yee Soon Ling1, Hao-Jan Liang1, Sheng-Han Lee1, Mei-Yun Hu2, Po-Nien Tsao3.
Abstract
Naphthalene, the most common polycyclic aromatic hydrocarbon, causes airway epithelium injury in mice. Repeated exposure of mice to naphthalene induces airway epithelia that are resistant to further injury. Previous studies revealed that alterations in bioactivation enzymes and increased levels of gamma-glutamylcysteine synthase in the bronchioles protect tolerant mice from naphthalene and its reactive metabolites. In our current study, tolerance was induced in male ICR mice using a total of 7 daily intraperitoneal injections of naphthalene (200 mg/kg). Both naphthalene-tolerant and non-tolerant mice were challenged with a dose of 300 mg/kg naphthalene on day 8 to investigate metabolite differences. The lungs, liver, and kidneys were collected for histopathology 24 h after the challenge dose. Bronchial alveolar lavage fluid (BALF) and both hydrophilic and hydrophobic extracts from each organ were analyzed using nuclear magnetic resonance (NMR)-based metabolomics. The histological results showed no observable injuries to the airway epithelium of naphthalene-tolerant mice when compared with the control. In contrast, airway injuries were observed in mice given a single challenge dose (injury mice). The metabolomics analysis revealed that the energy metabolism in the lungs of tolerant and injury mice was significantly perturbed. However, antioxidant metabolites, such as glutathione and succinate, were significantly increased in the lungs of tolerant mice, suggesting a role for these compounds in the protection of organs from naphthalene-induced electrophilic metabolites and free radicals. Damage to the airway cellular membrane, as shown by histopathological results and increased acetone in the BALF and perturbation of hydrophobic lung extracts, including cholesterol, phosphorylcholine-containing lipids, and fatty acyl chains, were observed in injury mice. Consistent with our histopathological results, fewer metabolic effects were observed in the liver and kidney of mice after naphthalene treatments. In conclusion, NMR-based metabolomics reveals possible mechanisms of naphthalene tolerance and naphthalene-induced toxicity in the respiratory system of mice.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25849086 PMCID: PMC4388704 DOI: 10.1371/journal.pone.0120429
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1PCA scores plot of the lungs, liver, and kidneys after naphthalene treatments.
PCA scores plot show the grouping of the NMR spectra of bronchial alveolar lavage fluid (BALF) and hydrophilic and hydrophobic metabolites extracted from the lungs (a), liver (b), and kidneys (c) of mice after various naphthalene treatments. ◆/―: control (vehicle), ■/—-: single challenge dose, ▲/…: repeated naphthalene treatment. Ellipses represent the mean ± SD of PC scores along PC axes for each group.
Significant changes of hydrophilic metabolites from the lung, liver, and kidney of mice after various naphthalene treatments.
| Fold change | |||||||
|---|---|---|---|---|---|---|---|
| Organs | ppm (multiplicity) | Metabolites | ANOVA ( | Injury / Control | Tolerance / Control | Tolerance / Injury | |
|
| 1.32 (d) | Lactate |
| 1.3 | 1.2 | 0.9 | |
| 1.50 (d) | Alanine |
| 1.2 | 1.2 | 1.0 | ||
| 2.12 (m), 2.46(m) | Glutamine |
| 1.0 | 1.3 | 1.2 | ||
| 2.40(s) | Succinate |
| 0.9 | 1.4 | 1.6 | ||
| 2.56 (m) | Glutathione |
| 1.1 | 1.7 | 1.6 | ||
| 3.23 (t), 4.64 (d) | Glucose |
| 0.9 | 0.6 | 0.6 | ||
| 8.2 (s), 8.61 (s) | AMP |
| 0.9 | 1.4 | 1.6 | ||
| BALF | 3.21 (s) | GPC+Phosphocholine |
| 2.9 | 1.4 | 0.5 | |
| 2.24 (s) | Acetone |
| 2.2 | 0.9 | 0.4 | ||
|
| 1.50 (d) | Alanine |
| 1.3 | 1.0 | 0.8 | |
| 2.56 (m) | Glutathione |
| 0.9 | 1.3 | 1.5 | ||
| 3.02 (s) | Creatine |
| 1.4 | 0.8 | 0.6 | ||
| 6.13 (d), 8.50 (s) | ADP |
| 1.6 | 1.0 | 0.6 | ||
| 6.33 (d), 8.30 (s) | Inosine |
| 0.6 | 1.0 | 1.7 | ||
| 8.2 (s), 8.61 (s) | AMP |
| 0.5 | 0.7 | 1.5 | ||
|
| 1.32 (d) | Lactate |
| 1.3 | 1.0 | 0.8 | |
| 1.90 (s) | Acetate |
| 0.8 | 0.8 | 0.9 | ||
| 3.02 (s) | Creatine |
| 1.8 | 0.8 | 0.5 | ||
| 3.50 (dd), 3.61 (t) | myo-Inositol |
| 1.1 | 0.9 | 0.9 | ||
aPeaks observed as singlet (s), doublet (d), Double doublet (dd), triplet (t), quartet(q), pentet (p), and multiplet (m)
∧The peaks selected for integration.
●, p value <0.05;
●●, p value <0.01;
●●●, p value <0.001
bFold changes of peak area relative to its corresponding. Values X > 1 and X < 1 represent increase and decrease relative to its corresponding.
Control- Administered with olive oil; Single- Administered with challenge dose (300mg/kg); Repeated- Repeated treated (200mg.kg) for 7 days and a challenge dose.
* The significant changes (p<0.05) of the identified metabolite by Sheffé’s test.
GPC: glycerophosphocholine
Significant changes of hydrophobic metabolites from the lung, liver, and kidney of mice after various naphthalene treatments.
| Fold change | |||||||
|---|---|---|---|---|---|---|---|
| Organs | ppm (multiplicity) | Metabolites | ANOVA ( | Injury/Control | Tolerance/Control | Tolerance/Injury | |
|
| 0.68 (s) | Total cholesterol C-18 |
| 1.1 | 0.9 | 0.9 | |
| 0.86 (d) | Total cholesterol C-26 |
| 1.1 | 0.9 | 0.9 | ||
| 0.92 (d) | Total cholesterol C-21 |
| 1.1 | 0.9 | 0.8 | ||
| 1.01 (s) | Free cholesterol C-19 |
| 1.1 | 0.9 | 0.8 | ||
| 0.89 (t) | Fatty acyl chain C |
| 0.9 | 1.1 | 1.1 | ||
| 1.26 (m) | Fatty acyl chain (C |
| 0.8 | 1.0 | 1.2 | ||
| 3.88 (s) | Phosphorylcholine-containing lipid C |
| 0.8 | 1.2 | 1.6 | ||
|
| 0.68 (s) | Total cholesterol C-18 |
| 1.2 | 1.0 | 0.9 | |
| 3.88 (s) | Phosphorylcholine-containing lipid C |
| 0.8 | 1.1 | 1.3 | ||
|
| 0.89 (t) | Fatty acyl chain C |
| 1.1 | 1.1 | 1.0 | |
aPeaks observed as singlet (s), doublet (d), Double doublet (dd), triplet (t), quartet(q), pentet (p), and multiplet (m)
∧The peaks selected for integration.
●, p value <0.05;
●●, p value <0.01
bFold changes of peak area relative to its corresponding. Values X > 1 and X < 1 represent increase and decrease relative to its corresponding.
Control- Administered with olive oil; Single- Administered with challenge dose (300mg/kg); Repeated- Repeated treated (200mg.kg) for 7 days and a challenge dose.
* The significant changes (p<0.05) of the identified metabolite by Sheffé’s test.
** The significant changes (p<0.01) of the identified metabolite by Sheffé’s test.
Fig 2Pathway illustrating metabolite changes in the lung after naphthalene treatments.
Simplified pathway illustrating metabolite changes in the lung after different naphthalene treatments. A ↑ and ↓ at first and second position indicates changes (p <0.05 by Scheffé’s method) in the single challenge dose and repeated naphthalene treatment groups, respectively, relative to the control. The ratio of the repeated treatment group and the single dose challenged group is given at the last position. “–”indicates insignificant changes in the metabolites.
Fig 3Pathway illustrating metabolite changes in the liver after naphthalene treatments.
Simplified pathway illustrating metabolite changes in the liver after different naphthalene treatments. A ↑ and ↓ at first and second position indicates changes (p <0.05 by Scheffé’s method) in the single challenge dose and repeated naphthalene treatment groups, respectively, relative to the control. The ratio of the repeated treatment group and the single dose challenged group is given at the last position. “–”indicates insignificant changes in the metabolites.
Fig 4Pathway illustrating metabolite changes in the kidney after naphthalene treatments.
Simplified pathway illustrating metabolite changes in the kidney after different naphthalene treatments. A ↑ and ↑ at first and second position indicates changes (p <0.05 by Scheffé’s method) in the single challenge dose and repeated naphthalene treatment groups, respectively, relative to the control. The ratio of the repeated treatment group and the single dose challenged group is given at the last position. “–”indicates insignificant changes in the metabolites.